93MO Optimal 18F-FDG PET/CT (FDG-PET) cut-off for pathological complete response (pCR) prediction in HER2-positive [HER2+] early breast cancer (EBC) patients (pts) treated with neoadjuvant trastuzumab (T) and pertuzumab (P) in PHERGain trial

G Gebhart,M Keyaerts,T Guiot,P Flamen,M Ruiz Borrego,A Stradella,B Bermejo De Las Heras,S Escriva De Romani,L Calvo-Martinez,N Ribelles Entrena,N Martinez,C.R Albacar Miro,M.A Colleoni,M Atienza De Frutos,M Sampayo-Cordero,J Cortés,J.M Perez Garcia,A Llombart Cussac

doi:10.1016/j.annonc.2022.03.109

93MO Optimal 18F-FDG PET/CT (FDG-PET) cut-off for pathological complete response (pCR) prediction in HER2-positive [HER2+] early breast cancer (EBC) patients (pts) treated with neoadjuvant trastuzumab (T) and pertuzumab (P) in PHERGain trial

G Gebhart, M Keyaerts + Show 16 more

Open Access

https://doi.org/10.1016/j.annonc.2022.03.109

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Publication Date: May 1, 2022

Affiliation: Institut Jules Bordet, Université Libre de Bruxelles, Universitair Ziekenhuis Brussel, Institut Català d'Oncologia, Vall d'Hebron Hospital Universitari, Complexo Hospitalario Universitario A Coruña, Hospital Clínico Universitario Virgen de la Victoria, Hospital Universitari Sant Joan de Reus, European Institute of Oncology, European University of Madrid, MedSIR (Spain), GEICAM – Spanish Breast Cancer Group, Hospital Arnau de Vilanova

#NeoALTTO Study #Maximum Standardized Uptake Value + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

PHERGain trial investigated the potential of metabolic imaging to identify candidates for chemotherapy (CT) de-escalation in HER2-positive, stage I-IIIA, invasive, operable breast cancer with at least one breast lesion evaluable by FDG-PET. Based on data from NeoALTTO study, FDG-PET “responders” were defined as those pts with maximum standardized uptake value (SUVmax) reduction of at least 40% in all their target lesions after two cycles of T and P. Of the 285 patients included in T+P arm, 227 pts were FDG-PET responders and received a total of 8 cycles of T+P.

Full Text